NCT02176070

Brief Summary

The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
467

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

May 30, 2014

Completed
27 days until next milestone

First Posted

Study publicly available on registry

June 26, 2014

Completed
Last Updated

June 26, 2014

Status Verified

June 1, 2014

Enrollment Period

1.1 years

First QC Date

May 30, 2014

Last Update Submit

June 25, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • The rate of infertility with and without prior cyc.

    1 year after the study is closed to enrollment

Secondary Outcomes (1)

  • The rate of pregnancy complications in pregnancies delivered before and after vasculitis diagnosis.

    1 year after the study is closed to enrollment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with vasculitis included in the VCRC Contact Registry were invited to participate. Data was included for all patients who provided a vasculitis diagnosis, estimated date of diagnosis, confirmed that the diagnosis was made by a rheumatologist, and reported having taken at least one appropriate anti-rheumatic medication. Other participants were excluded as the likelihood that they have a true vasculitis condition is low.

You may qualify if:

  • Enrolled in VCRC Contact Registry
  • Patient reported diagnosis of Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Takayasu's Arteritis, Giant Cell Arteritis, Behcet's Disease, Kawasaki Disease, Henoch-Schoenlein Purpura, CNS or Drug-induced Vasculitis
  • years of age or older
  • English speaking

You may not qualify if:

  • Inability to provide informed consent and complete survey

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of South Florida Data Management Coordinating Center

Tampa, Florida, 33612, United States

Location

MeSH Terms

Conditions

Giant Cell ArteritisTakayasu ArteritisPolyarteritis NodosaGranulomatosis with PolyangiitisMicroscopic PolyangiitisChurg-Strauss SyndromeBehcet SyndromeMucocutaneous Lymph Node SyndromeIgA VasculitisVasculitis, Central Nervous System

Condition Hierarchy (Ancestors)

Autoimmune Diseases of the Nervous SystemNervous System DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular DiseasesArteritisVasculitisSkin Diseases, VascularSkin DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesAortic Arch SyndromesAortic DiseasesSystemic VasculitisLung Diseases, InterstitialLung DiseasesRespiratory Tract DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCerebral Small Vessel DiseasesGranulomaLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesMouth DiseasesStomatognathic DiseasesUveitis, AnteriorPanuveitisUveitisUveal DiseasesEye DiseasesHereditary Autoinflammatory DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin Diseases, GeneticPurpuraBlood Coagulation DisordersHematologic DiseasesHemostatic DisordersHemorrhagic DisordersImmune Complex DiseasesHypersensitivityHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Study Officials

  • Megan Clowse, MD, MPH

    Duke University

    STUDY CHAIR
  • Amanda M. Terry, MA

    USF College of Medicine

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2014

First Posted

June 26, 2014

Study Start

February 1, 2011

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

June 26, 2014

Record last verified: 2014-06

Locations